Roche highlights new drugs

Legacy drugs accounted for half of pharmaceutical sales at Roche in 2017, but this was partially offset by strong growth for a group of recently launched products including new medicines for multiple sclerosis, haemophilia A and cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.